Physician profile
Gregory D Borowski
NPI 1104800341
$37,951.66
in general payments reported to CMS, 2019-2025
16 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $4,956 · 2021: $1,647 · 2022: $45.38 · 2023: $131 · 2024: $359 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,494.25 | 2019-2020 | |
| Lilly USA, LLC | $6,115.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,218.59 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,683.84 | 2021-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $546.29 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $261.00 | 2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Medtronic, INC. | $181.65 | 2023-2025 | Minimed 780g |
| Amgen INC. | $143.13 | 2025 | Tepezza |
| Insulet Corporation | $103.32 | 2019-2023 | Omnipod |
| Sequel Med Tech, LLC | $85.04 | 2025 | Twiist |
| Medtronic Minimed, INC. | $30.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.38 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $17.22 | 2025 | Yorvipath |
| Abbvie INC. | $15.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Borowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.